(GLOBE NEWSWIRE) -- (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious ...

Detailed price information for Lisata Therapeutics Inc (LSTA-Q) from The Globe and Mail including charting and trades.

CStone Pharmaceuticals (CStone, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and ...

M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the ...

Encouraging Phase 1 data on ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-⍺ (FR⍺), presented at the ...

The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

Data rich period continues to support certepetide’s broad applicability and effectivenessCatalent enters into global license agreement for the ...

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat ...

Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established ...

Advanced epithelial ovarian cancer is a critical focus within gynaecologic oncology, as it continues to pose significant clinical challenges due to frequent ...